VMS M&A Wave 2026: The Brand Playbook
The vitamins, minerals, and supplements sector is moving fast in 2026. Private equity is circling. Strategic acquirers are writing checks. And if you're running an independent supplement brand, the window to make a deliberate strategic move is narrowing with every deal that closes.
Here's what the current consolidation wave looks like, why it's accelerating, and what the smart money is doing next.
The Deals Defining the Moment
Q1 2026 has already produced a cluster of significant VMS transactions. Bioniq, the precision nutrition platform known for blood-test-driven supplement protocols, attracted private equity capital looking to own the personalized supplement infrastructure layer. ILS Gummies, a fast-growing functional gummy brand, was absorbed in a deal that underscores PE appetite for format-forward innovation with DTC traction. Western Botanicals, a heritage botanical extract brand with a loyal independent health retailer base, changed hands as consolidators moved to lock up supply-adjacent assets. And Huel, the UK-founded functional nutrition brand with a global footprint, completed a transaction that signals acquirers are no longer limiting their scope to pure-play supplement brands. Meal-replacement and complete-nutrition companies are firmly in scope.
These aren't isolated events. They reflect a structural shift in how capital views the supplement category. VMS has historically been fragmented, founder-led, and resistant to standardization. That fragmentation is now the feature, not a bug, for roll-up strategies.
Why Private Equity Is So Interested Right Now
The global supplement market is forecast to reach $430 billion by 2035. That's a long acquisition runway, and PE firms are building positions early. The category has a defensive growth profile. Consumers don't stop buying supplements when economic conditions soften. Repeat purchase rates are high. Subscription models are common. Customer acquisition costs, while rising across DTC channels, remain manageable relative to the lifetime value of a loyal supplement buyer.
Acquirers are specifically targeting brands with three attributes: proprietary formulations that can't be easily replicated by white-label competitors, loyal DTC customer bases with strong email and SMS data assets, and clean regulatory records. In a category where the FDA's oversight is evolving and international regulatory alignment is tightening, a brand with a spotless compliance history is worth a meaningful premium at close.
This consolidation dynamic mirrors what's playing out across adjacent fitness sectors. The Fitness M&A 2026 report from Houlihan Lokey identified similar roll-up logic driving gym operator acquisitions. The underlying thesis is the same: fragmented markets with predictable recurring revenue attract institutional capital at scale.
The Gruns Benchmark and What It Means for Valuation
Earlier in 2026, Unilever acquired Gruns for $1.2 billion. That number matters beyond the headline. Gruns built its business on personalization: gummies formulated to individual nutritional profiles, driven by intake questionnaires and increasingly by biomarker data. Unilever paid a strategic premium for that model, and the VMS investment community noticed.
The Gruns deal established a valuation benchmark that PE firms are now stress-testing across smaller targets. Brands that can demonstrate a credible personalization layer, whether through quiz-based customization, subscription flexibility, or lab-data integration, are being marked up relative to commodity supplement peers. The gap between a brand selling generic omega-3 softgels and a brand delivering monthly personalized stacks based on user health data is no longer philosophical. It's priced into deal multiples.
The personalization premium isn't unique to supplements. As explored in the $31B personalization market analysis, consumer willingness to pay for tailored health solutions is measurable and growing. Brands that have embedded personalization into their core product experience are sitting on a strategic asset that acquirers are willing to overpay for.
The Three-Way Fork for Independent Brands
If you're running an independent VMS brand right now, you're facing a genuinely consequential strategic decision. The consolidation wave doesn't leave room for comfortable inaction. Here's how the three main paths break down.
Scale through bolt-on acquisitions. Some independent brands are responding by becoming acquirers themselves. If you have a strong DTC base in one category, buying a complementary brand in an adjacent niche can build the multi-SKU, multi-category platform that makes you a more attractive acquisition target at a later stage. This path requires capital, operational bandwidth, and a clear thesis about what categories you're building toward. It's not a move for brands running lean.
Hyper-specialize to become a defensible target. The alternative to scale is depth. Brands that own a category niche so completely that acquirers see them as the only credible entry point into that niche command premium multiples. This means ruthless focus: one customer segment, one health outcome, one format done exceptionally well. A brand that's the definitive choice for, say, postpartum nutritional recovery or endurance athlete electrolyte optimization is harder to replicate than a general wellness brand with fifty SKUs. Specialization is a moat, and acquirers pay for moats.
Prepare for exit while multiples are elevated. The third path is the most time-sensitive. Deal multiples in VMS are high right now, driven by competition among PE firms for quality assets. That compression won't last indefinitely. Brands with strong financials, clean cap tables, and a repeatable growth story should be asking whether the current environment represents the best exit window they'll see in the next several years. Preparing for exit isn't capitulation. It's disciplined capital allocation.
The specialist-versus-generalist tension plays out in supplement brands the same way it does in professional services. The revenue and valuation gap between a deeply specialized brand and a broad-but-shallow one is widening, just as the 2026 revenue gap between specialist and generalist coaches has become increasingly difficult to ignore.
The CDMO Risk That Most Brands Are Underestimating
There's a second consolidation story running in parallel to branded VMS M&A, and it's getting less attention than it deserves. Contract development and manufacturing organizations (CDMOs) are being absorbed at a significant rate. Private equity is rolling up the manufacturing infrastructure of the supplement industry at the same time it's rolling up the brands.
This creates a material supply chain concentration risk. If your brand relies on a single CDMO for formulation and production, and that CDMO gets acquired by a platform that prioritizes its own branded products or its largest volume customers, you're exposed. Lead times extend. Minimum order quantities shift. Pricing power moves to the acquirer.
Brands that haven't diversified their manufacturing relationships need to address this now, not after a supply disruption forces the issue. Qualifying a secondary CDMO, even if it's not your primary production partner, is a straightforward operational hedge. The brands that will navigate this consolidation wave cleanly are the ones treating their supply chain as a strategic asset rather than a procurement function.
What Operators and Coaches in Adjacent Fitness Categories Should Watch
The VMS consolidation wave has direct downstream implications for fitness professionals who recommend or distribute supplements as part of their service model. As branded supplement lines get absorbed into larger platforms, the independent brands that coaches and gyms have built relationships with may change ownership, pricing structures, or distribution terms without warning.
For gym operators, the lesson from parallel consolidation trends applies here too. The Playlist x EGYM merger's implications for gym operators demonstrated how upstream consolidation reshapes the terms that downstream businesses operate under. VMS consolidation follows the same logic.
For coaches who've built supplement recommendations into their client programs, this is a moment to audit those relationships and consider how dependent your client experience is on any single brand continuing to operate as it currently does. Diversifying your supplement recommendation stack, the same way you'd diversify any vendor dependency, is prudent risk management.
The Strategic Reality for 2026 and Beyond
The VMS M&A wave of 2026 isn't a temporary spike. The structural drivers, PE capital availability, a $430 billion market forecast, the Gruns valuation benchmark, CDMO consolidation pressure, are durable. Deals will keep closing through 2026 and into 2027.
For independent supplement brands, the strategic imperative is clarity. Know which path you're on. Scale deliberately, specialize ruthlessly, or prepare for exit with the same rigor you'd bring to any major business decision. The brands that drift through this period without a defined posture will find themselves with fewer options and less leverage as the landscape compresses around them.
The market is being restructured. You get to decide whether that restructuring happens to you or around you.